TOSLA and Geltor Launch the First Vegan Signaling Collagen Liquid Supplement, Powered by PrimaColl, a Type 21 Signaling Collagen

Why It Matters

The partnership brings biotech‑engineered, plant‑based collagen to mainstream consumers, unlocking a new growth segment for beauty‑from‑within brands and accelerating the shift toward vegan nutraceuticals.

Key Takeaways

• First vegan type 21 signaling collagen in ready‑drink format
• 1 g PrimaColl per 30 mL bottle delivers skin‑firmness benefits
• Clinical trial showed 80‑92% improvement in skin metrics over 12 weeks
• TOSLA’s VELIOUS technology improves taste, boosting daily adherence
• Launch targets beauty‑from‑within brands at Vitafood and NYSCC events

Pulse Analysis

The collagen supplement market, long dominated by animal‑derived hydrolysates, is undergoing a rapid transformation as consumers demand plant‑based and clean‑label options. TOSLA’s partnership with Geltor introduces the first vegan type 21 signaling collagen, PrimaColl, into a ready‑to‑drink format, signaling a shift from powders to convenient liquid rituals. This move aligns with the broader nutricosmetics trend, where efficacy, taste, and habit formation are equally prized. By leveraging biotech‑engineered polypeptides, the product bridges the gap between scientific innovation and everyday wellness consumption. The global collagen market, projected to exceed $7 billion by 2028, is increasingly driven by vegan alternatives.

PrimaColl is a biomimetic type 21 collagen polypeptide that engages skin‑signaling pathways, a function traditionally unavailable in plant‑based ingredients. In a double‑blind, placebo‑controlled study of 170 women, 80‑92% experienced measurable gains in firmness, elasticity, moisturisation and wrinkle depth after 12 weeks of 1‑2.5 g daily intake. Although the ingredient holds FDA GRAS status, it still requires pre‑market authorisation in the EU, UK and Canada, underscoring the regulatory nuances that biotech nutraceuticals must navigate before global rollout. Consumers appreciate the GRAS designation as a safety signal, even as regulatory gaps persist.

The collaboration positions TOSLA and Geltor as early movers in the emerging ingestible beauty segment, offering a turnkey solution for brands eager to launch vegan collagen products without building their own biotech pipelines. The inclusion of VELIOUS flavour technology addresses the historic adherence barrier of collagen supplements, turning daily intake into a pleasant ritual. As retailers and e‑commerce platforms expand their nutricosmetics shelves, the Signaling Collagen Shot could become a reference product, prompting competitors to pursue similar biotech‑driven, ready‑to‑drink formulations. If adoption accelerates, the product may catalyze a broader shift toward biotech‑based nutraceuticals across categories.